<DOC>
	<DOCNO>NCT02110394</DOCNO>
	<brief_summary>Prospective multicenter observational non-interventional study ass routine clinical practice Bendamustine use first line therapy chronic lymphocytic leukemia</brief_summary>
	<brief_title>Ribomustin First Line Therapy Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients chronic lymphocytic leukemia ( CLL ) current plan first line therapy Ribomustin Informed Consent Form personal data handle sign program participant Any prior chemotherapy and/or radiotherapy and/or immunotherapy and/or investigational agent treatment CLL Currently participate clinical trial , and/or take investigational drug within 28 day prior enrollment Contraindications Ribomustin usage accordance product label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>observational</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>bendamustine</keyword>
</DOC>